Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

94
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
94
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

123
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
123
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Differentiated service delivery and self-care in HIV.

The lancet. HIV·2026
Same author

Africa's ownership of a sustainable health journey towards an AIDS-free future.

BMJ global health·2026
Same author

Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.

Nature communications·2026
Same author

Editorial Expression of Concern: The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.

Nature·2026
Same author

Advancing global health access through market shaping: Cases and learnings.

PLOS global public health·2026
Same author

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Communications medicine·2025

Related Experiment Video

Updated: Nov 27, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K

Multi-stakeholder consensus on a target product profile for an HIV cure.

Sharon R Lewin1, Timothy Attoye2, Cathy Bansbach3

  • 1The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.

The Lancet. HIV
|December 3, 2020
PubMed
Summary

Developing an HIV cure is a global priority. Experts agreed on target product profiles for HIV cures, including gene therapies, with an acceptable cure not needing to match antiretroviral therapy safety.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.9K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.0K

Related Experiment Videos

Last Updated: Nov 27, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.9K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.0K

Area of Science:

  • Infectious Diseases
  • Biotechnology
  • Public Health

Background:

  • Developing a cure for Human Immunodeficiency Virus (HIV) is a critical global health objective.
  • Target product profiles (TPPs) are essential tools in drug development, aligning stakeholders on product requirements.
  • Existing HIV treatments, while effective, do not provide a cure, necessitating research into novel therapeutic strategies.

Purpose of the Study:

  • To identify and define target product profiles for an HIV cure.
  • To explore distinct therapeutic modalities for achieving an HIV cure, including combination therapies, ex-vivo gene therapy, and in-vivo gene therapy.
  • To establish consensus among experts on the criteria for an optimal and acceptable HIV cure.

Main Methods:

  • Expert consultations, including face-to-face meetings and an online Delphi process, were employed.
  • The study involved identifying key criteria for target product profiles for HIV cure interventions.
  • A consensus-building approach was used to define the attributes of an acceptable HIV cure.

Main Results:

  • A high degree of agreement was reached on the criteria for an optimum target product profile for an HIV cure.
  • Three primary therapeutic modalities were identified: combination therapies, ex-vivo gene therapy, and in-vivo gene therapy.
  • Consensus indicated that an acceptable HIV cure need not be as safe and effective as current antiretroviral therapy.

Conclusions:

  • Target product profiles for HIV cures have been defined, guiding future research and development.
  • An intervention curing a significant fraction of adults is considered sufficient for clinical advancement.
  • These TPPs will evolve as scientific understanding and therapeutic technologies advance in the field of HIV cure research.